All In Biotech

NDA 019908 · Cosette

Ambien

Zolpidem Tartrate · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Feb 23, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1992

Dec 16, 1992

Approved uses

2

Original approval plus efficacy supplements

Registered trials

142

25 Phase 3, 8 recruiting

FAERS reports

82,817

52,480 serious, 7,310 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: COMPLEX SLEEP BEHAVIORS Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of AMBIEN. Some of these events may result in serious injuries, including death. Discontinue AMBIEN immediately if a patient experiences a complex sleep behavior [see Contraindications (4) and Warnings and Precautions (5.1) ]. WARNING: COMPLEX SLEEP BEHAVIORS See full prescribing information for complete boxed warning. Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of AMBIEN. Some of these events may result in serious injuries, including death. Discontinue AMBIEN immediately if a patient experiences a complex sleep behavior. ( 4 , 5.1 )

What it is approved for

From the label in effect Feb 7, 2025.

AMBIEN (zolpidem tartrate) is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. AMBIEN has been shown to decrease sleep latency for up to 35 days in controlled clinical studies [see Clinical Studies (14) ] . The clinical trials performed in support of efficacy were 4–5 weeks in duration with the final formal assessments of sleep latency performed at the end of treatment. AMBIEN, a gamma-aminobutyric acid (GABA) A receptor positive modulator, is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. ( 1 )

Mechanism: Zolpidem is a GABA A receptor positive modulator presumed to exert its therapeutic effects in the short-term treatment of insomnia through binding to the benzodiazepine site of α1 subunit containing GABA A receptors, increasing the frequency of chloride channel opening resulting in the inhibition of neuronal excitation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • AMBIEN · ZOLPIDEM TARTRATE 10MG · TABLET, ORAL · Prescription · TE AB
  • AMBIEN · ZOLPIDEM TARTRATE 5MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Zolpidem" as an intervention, any sponsor and status, largest first.

All 142 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea5,914
  • fatigue5,777
  • drug ineffective5,689
  • insomnia4,680
  • pain4,603
  • headache4,367
  • diarrhoea4,059
  • anxiety3,815
  • dizziness3,689
  • dyspnoea3,615
  • fall3,517
  • depression3,309

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,922
20052,499
20063,251
20073,022
20082,367
20093,104
20103,728
20113,508
20124,600
20133,772
20143,793
20155,836
20166,337
20174,788
20185,961
20194,567
20203,762
20212,842
20222,909
20232,650
20242,755
20252,793
20262,046

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ambien (Zolpidem Tartrate)

2024 spending

$10.4M

Beneficiaries

2,323

13,186 claims

Per beneficiary

$4,464

$20.68 per unit

View as table
YearSpending
2020$12,961,930
2021$12,822,930
2022$12,634,406
2023$12,138,036
2024$10,369,529

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 490 on PubMed

Sponsor: Cosette

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.